Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...
A novel combination of an investigational intravesical drug delivery system designed to provide sustained release of gemcitabine into the bladder (Gem-iDRS, Inlexzo) and systemic treatment with the ...
Injections and infusions are a common way to receive chemotherapy. Both methods deliver cancer-treating medications directly into the bloodstream. Chemotherapy is a common cancer treatment that uses ...
Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, reducing disease progression or death risk by 60%. The EV-303/KEYNOTE-905 trial ...
The FDA has approved atezolizumab and atezolizumab with hyaluronidase-tqjs as adjuvant treatment for certain adults with ...
Adding pembrolizumab to trimodality therapy is feasible as a bladder-sparing approach for MIBC and showed an acceptable complete response rate in a phase 2 trial. In a phase 2 trial, pembrolizumab ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
The incorporation of radiation therapy with radiosensitizing chemotherapy marked a pivotal advancement, establishing trimodality therapy (TMT) as the foundation of contemporary bladder preservation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results